Ascelia Pharma has conducted a private placement of SEK 98.7 million through a new issue of approximately 4.7 million shares at a price of SEK 21 per share. The new issue was directed at a number of Swedish and international institutional investors. The proceeds will be used to accelerate the pre-commercial activities for the planned launch of the product candidate Mangoral, which is currently in the Phase 3 clinical study SPARKLE, as well as for general corporate purposes. Setterwalls has acted as legal advisor to Ascelia Pharma in connection with the private placement.
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ACE).